Summary
Global Markets Direct’s, ‘Systemic Mastocytosis - Pipeline Review, H1 2016’, provides an overview of the Systemic Mastocytosis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Systemic Mastocytosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Systemic Mastocytosis and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Systemic Mastocytosis
- The report reviews pipeline therapeutics for Systemic Mastocytosis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Systemic Mastocytosis therapeutics and enlists all their major and minor projects
- The report assesses Systemic Mastocytosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Systemic Mastocytosis
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Systemic Mastocytosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Systemic Mastocytosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
AB Science SA
AbbVie Inc.
Allakos Inc.
Arog Pharmaceuticals, Inc.
Blueprint Medicines Corporation
Bristol-Myers Squibb Company
Deciphera Pharmaceuticals, LLC
Novartis AG
Patara Pharma, Inc.
Stemline Therapeutics, Inc.
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Systemic Mastocytosis Overview 7
Therapeutics Development 8
Pipeline Products for Systemic Mastocytosis - Overview 8
Pipeline Products for Systemic Mastocytosis - Comparative Analysis 9
Systemic Mastocytosis - Therapeutics under Development by Companies 10
Systemic Mastocytosis - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Systemic Mastocytosis - Products under Development by Companies 14
Systemic Mastocytosis - Companies Involved in Therapeutics Development 15
AB Science SA 15
AbbVie Inc. 16
Allakos Inc. 17
Arog Pharmaceuticals, Inc. 18
Blueprint Medicines Corporation 19
Bristol-Myers Squibb Company 20
Deciphera Pharmaceuticals, LLC 21
Novartis AG 22
Patara Pharma, Inc. 23
Stemline Therapeutics, Inc. 24
Systemic Mastocytosis - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
AK-002 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
BLU-285 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
crenolanib besylate - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
cromolyn sodium - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
dasatinib - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
DCC-2618 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
ibrutinib - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
masitinib - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
midostaurin - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
SL-401 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Systemic Mastocytosis - Recent Pipeline Updates 61
Systemic Mastocytosis - Discontinued Products 98
Systemic Mastocytosis - Product Development Milestones 99
Featured News & Press Releases 99
May 02, 2016: AB Science has submitted to EMA the marketing authorization application for Masitinib in the Treatment of Severe Systemic Mastocytosis 99
Feb 01, 2016: AB Science announces that Rapporteurs appointed by the EMA have recommended to file a marketing authorization application for full approval for masitinib in severe systemic mastocytosis 99
Dec 07, 2015: AB Science announces results from Phase 3 randomized placebo-controlled trial of masitinib in adults with severe systemic mastocytosis unresponsive to optimal symptomatic treatment 102
Nov 30, 2015: AB Science Announces Positive Top-Line Results from Phase 3 Trial of Masitinib in Adults with Severe Systemic Mastocytosis 104
Sep 10, 2015: Blueprint Medicines Receives FDA Authorization to Advance Novel Drug Candidate into Clinical Trial for Systemic Mastocytosis 105
Dec 08, 2014: Blueprint Medicines Debuts Comprehensive Preclinical Data Set on First Selective Drug for Patients with Systemic Mastocytosis at 2014 American Society of Hematology Annual Meeting 106
Appendix 107
Methodology 107
Coverage 107
Secondary Research 107
Primary Research 107
Expert Panel Validation 107
Contact Us 107
Disclaimer 108
List of Tables
Number of Products under Development for Systemic Mastocytosis, H1 2016 8
Number of Products under Development for Systemic Mastocytosis - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Comparative Analysis by Late Stage Development, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 12
Comparative Analysis by Early Stage Development, H1 2016 13
Products under Development by Companies, H1 2016 14
Systemic Mastocytosis - Pipeline by AB Science SA, H1 2016 15
Systemic Mastocytosis - Pipeline by AbbVie Inc., H1 2016 16
Systemic Mastocytosis - Pipeline by Allakos Inc., H1 2016 17
Systemic Mastocytosis - Pipeline by Arog Pharmaceuticals, Inc., H1 2016 18
Systemic Mastocytosis - Pipeline by Blueprint Medicines Corporation, H1 2016 19
Systemic Mastocytosis - Pipeline by Bristol-Myers Squibb Company, H1 2016 20
Systemic Mastocytosis - Pipeline by Deciphera Pharmaceuticals, LLC, H1 2016 21
Systemic Mastocytosis - Pipeline by Novartis AG, H1 2016 22
Systemic Mastocytosis - Pipeline by Patara Pharma, Inc., H1 2016 23
Systemic Mastocytosis - Pipeline by Stemline Therapeutics, Inc., H1 2016 24
Assessment by Monotherapy Products, H1 2016 25
Number of Products by Stage and Target, H1 2016 27
Number of Products by Stage and Mechanism of Action, H1 2016 29
Number of Products by Stage and Route of Administration, H1 2016 31
Number of Products by Stage and Molecule Type, H1 2016 33
Systemic Mastocytosis Therapeutics - Recent Pipeline Updates, H1 2016 61
Systemic Mastocytosis - Discontinued Products, H1 2016 98
List of Figures
Number of Products under Development for Systemic Mastocytosis, H1 2016 8
Number of Products under Development for Systemic Mastocytosis - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Comparative Analysis by Clinical Stage Development, H1 2016 12
Assessment by Monotherapy Products, H1 2016 25
Number of Products by Top 10 Targets, H1 2016 26
Number of Products by Stage and Top 10 Targets, H1 2016 26
Number of Products by Top 10 Mechanism of Actions, H1 2016 28
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 28
Number of Products by Routes of Administration, H1 2016 30
Number of Products by Stage and Routes of Administration, H1 2016 30
Number of Products by Molecule Types, H1 2016 32
Number of Products by Stage and Molecule Types, H1 2016 32
